Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2017 Apr;69(4):863-865.
doi: 10.1002/art.39981. Epub 2017 Mar 3.

Reanalysis of the Multi-Biomarker Disease Activity Score for Assessing Disease Activity in the Abatacept Versus Adalimumab Comparison in Biologic-Naive Rheumatoid Arthritis Subjects with Background Methotrexate Study: Comment on the Article by Fleischmann et al

Jeffrey R Curtis  1 , Grace C Wright  2 , Vibeke Strand  3 , Charles S Davis  4 , Elena Hitraya  5 , Eric H Sasso  5
Affiliations
Comment

Reanalysis of the Multi-Biomarker Disease Activity Score for Assessing Disease Activity in the Abatacept Versus Adalimumab Comparison in Biologic-Naive Rheumatoid Arthritis Subjects with Background Methotrexate Study: Comment on the Article by Fleischmann et al

Jeffrey R Curtis et al. Arthritis Rheumatol. 2017 Apr.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Sensitivity analysis examining the association between radiographic progression and multi‐biomarker disease activity (MBDA) score in the AMPLE study (Abatacept versus Adalimumab Comparison in Biologic‐Naive Rheumatoid Arthritis Subjects with Background Methotrexate). Percentages of patients with radiographic progression at year 1 were analyzed by year 1 MBDA category for the abatacept arm and adalimumab arm, using published data from Fleischmann et al 1. Progressors were defined as having changes in the modified total Sharp score (ΔmTSS) exceeding the smallest detectable change (SDC) 1. The number of progressors in an individual MBDA category (low, moderate, or high) was determined in 2 steps. First, the total number of progressors in the 3 MBDA categories was calculated by subtracting the total number of nonprogressors, summed from Figure 2D in the report by Fleischmann and colleagues, from the total number of patients, obtained from Supplementary Table 5 in their report 1. Next, the total number of progressors was distributed across the 3 MBDA categories in 2 scenarios, representing the most extreme possibilities compatible with the reported data: Scenario 1 (least conservative) assigned all progressors to the highest possible MBDA categories; Scenario 2 (most conservative) assigned all progressors to the lowest possible MBDA categories (for numerical details, see Supplementary Tables 1 and 2, on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.39981/abstract). N values on the x‐axis are the number of patients in the MBDA category, i.e., the sum of progressors (P) and nonprogressors (NP) in that MBDA category. The percentage of patients with radiographic progression in each MBDA category is 100 × (P/[P + NP]). Statistical significance was determined by Mantel‐Haenszel test for trend, assuming ordinality in the MBDA categories.
See this image and copyright information in PMC

Comment in

  • Reply.
    Fleischmann R, Connolly SE, Maldonado MA, Schiff M. Fleischmann R, et al. Arthritis Rheumatol. 2017 Apr;69(4):867-868. doi: 10.1002/art.40021. Epub 2017 Feb 28. Arthritis Rheumatol. 2017. PMID: 27992708 No abstract available.

Comment on

References

    1. Fleischmann R, Connolly SE, Maldonado MA, Schiff M. Estimating disease activity using multi‐biomarker disease activity scores in rheumatoid arthritis patients treated with abatacept or adalimumab. Arthritis Rheumatol 2016;68:2083–9. - PMC - PubMed
    1. Weinblatt ME, Schiff M, Valente R, van der Heijde D, Citera G, Zhao C, et al. Head‐to‐head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum 2013;65:28–38. - PMC - PubMed
    1. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty‐eight–joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44–8. - PubMed
    1. Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005;7:R796–806. - PMC - PubMed
    1. Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, et al. A Simplified Disease Activity Index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 2003;42:244–57. - PubMed